Premium
Prophylactic cranial irradiation for limited non‐small cell lung cancer
Author(s) -
Griffin Brian R.,
Livingston Robert B.,
Stewart Glenn R.,
Higano Celestia,
Russell Kenneth J.,
Griffin Thomas W.,
Laramore George E.
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19880701)62:1<36::aid-cncr2820620109>3.0.co;2-i
Subject(s) - medicine , prophylactic cranial irradiation , conventional pci , radiation therapy , adenocarcinoma , chemotherapy , lung cancer , small cell carcinoma , radiology , lung , carcinoma , cancer , surgery , oncology , myocardial infarction
Seventy‐three patients with biopsy‐proven limited non‐small cell lung cancer (NSCLC) were entered on a combined modality study at the University of Washington. Seventy‐five percent (55 of 73) of the patients had a histologic diagnosis of adenocarcinoma or large cell carcinoma, whereas 25% (18 of 73) had squamous cell carcinoma. After two cycles of chemotherapy, patients without evidence of progressive disease received prophylactic cranial irradiation (PCI) and chest radiotherapy, followed by two additional cycles of chemotherapy. Brain computed tomography (CT) scans were performed at 3‐month intervals after completion of therapy in all patients, and were additionally performed whenever signs or symptoms developed suggesting neurologic dysfunction or recurrent brain disease. Sixty‐five patients were treated with PCI. No clinical or CT evidence of recurrence in the brain has developed in patients who completed PCI. PCI appears to be effective in greatly reducing the incidence of brain relapse in patients with limited NSCLC.